Advertisement
News
Advertisement

Tolerx, GSK diabetes drug candidate misses goal

Sun, 03/13/2011 - 8:37pm
Mass High Tech: The Journal of New England Technology

A Phase 3 clinical study of a type 1 diabetes treatment by Cambridge biotech Tolerx Inc., in conjunction with British pharmaceutical giant GlaxoSmithKline, failed to meet its primary endpoint.

The study evaluated otelixizumab, a monoclonal antibody drug target, for which the companies had set a primary endpoint goal of seeing a change in C-peptide after a year in patients with type 1 diabetes.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading